Literature DB >> 1423282

In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327.

J Y Chapelon1, J Margonari, F Vernier, F Gorry, R Ecochard, A Gelet.   

Abstract

High-intensity ultrasound has been used to treat Dunning R3327 prostatic adenocarcinoma implanted s.c. in Fischer Copenhagen rats. Focused ultrasound was generated with a 1-MHz transducer and energy was provided by a 7.5-kW power amplifier. Seventy-four rats were treated using two different sublines of Dunning tumor. Study 1 dealt with 49 rats with the Mat-Ly-Lu subline, treated with acoustic intensities ranging from 300 to 2750 W/cm2. Of the 49 rats in Study 1, 30 had complete tumor necrosis and 19 had no effect; of the 30 who had complete local tumor necrosis, 14 had local relapse, 9 had distance metastases to lung and nodes without local occurrence, and 7 remained free of tumor and were still alive 12 months after treatment. In Study 2, 25 rats with AT2 subline were treated with an intensity of 820 W/cm2. Similarly for Study 2, there was complete local tumor necrosis in 24 of 25 animals, with local regrowth in 7 of 24 and no recurrence of metastasis in the remaining 16 after a follow-up of 3 months. These results suggested that high-intensity focused ultrasound could be useful for the treatment of small localized cancerous tumors such as low-grade prostate carcinoma.

Entities:  

Mesh:

Year:  1992        PMID: 1423282

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Investigation of intensity thresholds for ultrasound tissue erosion.

Authors:  Zhen Xu; J Brian Fowlkes; Achi Ludomirsky; Charles A Cain
Journal:  Ultrasound Med Biol       Date:  2005-12       Impact factor: 2.998

Review 2.  The role of high-intensity focused ultrasound in prostate cancer.

Authors:  John H Lynch; Stacy Loeb
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

3.  Effects of acoustic parameters on bubble cloud dynamics in ultrasound tissue erosion (histotripsy).

Authors:  Zhen Xu; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  J Acoust Soc Am       Date:  2007-07       Impact factor: 1.840

4.  Optical and acoustic monitoring of bubble cloud dynamics at a tissue-fluid interface in ultrasound tissue erosion.

Authors:  Zhen Xu; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  J Acoust Soc Am       Date:  2007-04       Impact factor: 1.840

5.  High speed imaging of bubble clouds generated in pulsed ultrasound cavitational therapy--histotripsy.

Authors:  Zhen Xu; Mekhala Raghavan; Timothy L Hall; Ching-Wei Chang; Mary-Ann Mycek; J Brian Fowlkes; Charles A Cain
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2007-10       Impact factor: 2.725

6.  MRI-compatible positioning device for guiding a focused ultrasound system for transrectal treatment of prostate cancer.

Authors:  Christos Yiallouras; Nicos Mylonas; Christakis Damianou
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-12-13       Impact factor: 2.924

7.  Key factors that affect sonoporation efficiency in in vitro settings: the importance of standing wave in sonoporation.

Authors:  Manabu Kinoshita; Kullervo Hynynen
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

8.  High-intensity focused ultrasound induced apoptosis with caspase 3, 8, and 9/6 activation in rat hepatoma.

Authors:  Naoki Hirokawa; Kazumitsu Koito; Futoshi Okada; Nobuki Kudo; Katsuyuki Yamamoto; Katsuhiko Fujimoto; Mutsumi Nishida; Takeshi Ichimura; Masakazu Hori; Taishi Satoh; Masato Hareyama
Journal:  J Med Ultrason (2001)       Date:  2009-09-04       Impact factor: 1.314

9.  Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future.

Authors:  Luigi Mearini; Massimo Porena
Journal:  Indian J Urol       Date:  2010 Jan-Mar

10.  [HIFU in urological oncology].

Authors:  S Thüroff; C Chaussy
Journal:  Urologe A       Date:  2008-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.